NCT07739017Not yet recruitingPhase 1
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
A Phase 1, Two-Part, Accelerated Dose Titration Trial of CT-179 as Monotherapy in the Treatment of Recurrent Glioblastoma and in Combination With Radiation Therapy in the Treatment of Newly Diagnosed MGMT-Unmethylated Glioblastoma
Source: ClinicalTrials.gov · Last updated 28 Oct 2026
Brief summary (registry, in English)
This is a first-in-human Phase 1 two-part, open-label, multi-center, dose escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and maximum tolerated dose (MTD) of CT-179 in patients with recurrent glioblastoma and newly diagnosed MGMT-unmethylated glioblastoma who are eligible to receive radiation therapy following surgery, and to establish the recommended Phase 2 dose.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- First submitted
- 29 Apr 2026
- Start date
- Dec 2026
- Primary completion date
- Jun 2028
- Lead sponsor
- Olivia Newton-John Cancer Research Institute
- Diseases
- Glioblastoma
- NCT number
- NCT07739017
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 54
- From Dec 2026 to the primary completion date, Jun 2028
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Treatment with an investigational agent within the last 30 days excluding 5- aminolevulinic acid (5-ALA)
- Placement of Gliadel wafers or similar local therapy at time of surgery
- Receive bevacizumab
- Significant concomitant disorder or serious intercurrent illness
- Dose of dexamethasone higher than 4 mg/day within 1 week of the first dose of study medication
Other illness
- Evidence of intracranial or intra-tumoral hemorrhage
- History of prior malignancy, except adequately treated non-melanoma skin cancer, carcinoma in-situ of the cervix, or disease-free for more than 5 years
- Treatment for HIV, hepatitis B, or hepatitis C
- Any gastrointestinal disorder that could result in reduced absorption of CT-179
- Any psychiatric illness or social situation that would limit compliance with study requirements
Who the study is looking for
- Male or female aged ≥ 18 years at the time of signing informed consent
- Supratentorial, histologically confirmed diagnosis of primary GBM that meets the current diagnostic classification: 2021 WHO Classification of Tumors of the Central Nervous System
- KPS score ≥ 70
- Adequate organ function
- Contraception during study participation, as applicable
- Able to swallow tablets
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Alexandra Hospital Coordinator of this site? Confirm its status | Brisbane | Australia | Unknown status |
| Austin Health Coordinator of this site? Confirm its status | Heidelberg | Australia | Unknown status |
| Royal Brisbane and Women's Hospital Coordinator of this site? Confirm its status | Herston | Australia | Unknown status |
| The Alfred Hospital Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| St Vincent's Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
| Royal North Shore Hospital Coordinator of this site? Confirm its status | Sydney | Australia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.